---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-23-000076"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:01:36.862269+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio signs $30M promissory note with Nant Capital (SOFR+8%, due Dec 31, 2023)

## Summary
- Three $10M advances available; interest at Term SOFR + 8% per annum payable quarterly.
- Net proceeds ~$29.85M after $150k origination fee (0.5%) paid to lender.
- Proceeds to fund pre-commercialization, clinical development, R&D, capex, and general corporate purposes.
- Lender Nant Capital is affiliate of Executive Chairman Dr. Patrick Soon-Shiong (related-party transaction).
- Annual meeting results: all nine director nominees re-elected; Ernst & Young ratified as auditor.

## SEC filing metadata
- accession: 0001326110-23-000076
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/ibrx-20230613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-23-000076
- JSON: https://secwatch.observer/filing/0001326110-23-000076.json
- Plain text: https://secwatch.observer/filing/0001326110-23-000076.txt

## Key facts
- Debt Financings
  ImmunityBio, Inc. incurred loan of $30.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.
  - Instrument: loan
  - Principal: $30.0 million
  - Counterparty: Nant Capital, LLC
  - Rate: Term SOFR plus 8.0% per annum
  - Maturity: December 31, 2023
  - Event: incurrence
  source text: on June 13, 2023, the Company executed a $30.0 million promissory note with Nant Capital, LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm
- Shareholder Votes
  ImmunityBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Votes “For” Votes “Against” Abstentions “Broker Non-Votes” 374,132,354 270,094 278,602 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm
- Shareholder Votes
  ImmunityBio, Inc. shareholders approved Election of Nine Directors at the 2023-06-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: Nominee Votes “For” Votes “Withheld” “Broker Non-Votes” Patrick Soon-Shiong, M.D. 334,538,179 6,075,920 34,066,951 Cheryl L. Cohen 339,932,285 681,814 34,066,951 Richard Adcock 339,531,860 1,082,239 34,066,951 Michael D. Blaszyk 339,884,168 729,931 34,066,951 John Owen Brennan 337,964,499 2,649,600 34,066,951 Wesley Clark 338,703,037 1,911,062 34,066,951 Linda Maxwell, M.D. 340,016,716 597,383 34,066,951 Christobel Selecky 339,831,897 782,202 34,066,951 Barry J. Simon, M.D. 337,635,450 2,978,649 34,066,951
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.